Navigation Links
Biocon To Shift Focus On Innovation To Accelerate Growth

Biocon Ltd, India's largest biotechnology firm, has made a paradigm shift from being a generic drug manufacturer to innovation to drive its future growth aggressively. //

"We are rapidly transforming from a generics API (active pharmaceutical ingredients) manufacturer into an innovator for developing a robust pipeline of new molecules.

"We believe this strategy will deliver strong and sustainable growth in the future," Biocon chairperson Kiran Mazumdar-Shaw told reporters here Thursday.

Giving the company's outlook for the current fiscal (2006-07), Shaw said the year ahead would continue to be challenging due to uncertainties in market conditions and the impact of depreciation at its new facilities in the biotech park.

"We believe our balanced portfolio of products and services will deliver superior shareholder value over the medium and long-term. We expect our insulin products to gain substantial market share both in India and overseas markets," Shaw said.

The company, however, did not give any revenue guidance figure for the current fiscal or its first quarter (April-June) of FY 2007 as the biotech sector is evaluated on a medium to long-term basis, given the gestational nature of its R&D investments and regulatory time lines.

According to Biocon chief operating officer (COO) Arun Chandavarkar, the company's innovation strategy was built on in-house capabilities, proprietary technologies and a broad array of licensing and alliance partners the world over.

"Our focus on IP (intellectual property) and technology continues to be a strong differentiator. We have invested Rs.760 million in R&D capabilities during fiscal 2005-06, which is an increase of 76 percent over the previous fiscal (2004-05)," Chandavarkar said.

On the acquisition of the US-based Nobex portfolio for $5 million, Shaw said the company would leverage the proprietary intellectual (IP) assets through a combination of in-ho
'"/>




Page: 1 2

Related medicine news :

1. Biocon to colloborate for development of Oral peptide drugs for heart diseases.
2. Biocon To Raise Its Investment In Scotland
3. Kalam Dedicates New Cancer Drug Developed By Biocon
4. Bayer to Market Biocon Insulin in China
5. Biocon Launches Anti-Cancer Drug
6. Biocon to Launch Anti-arthritis Drug
7. Biocon Unveils Renal Therapies for Kidney Disorders
8. Biocon Net Profit Up by 15 Percent for Fiscal Year
9. Govt to Shift its Focus From Curative to Preventive Mode of Healthcare
10. Sex Ends as Seasons Shift and Kisspeptin Levels Plummet
11. Doctors Advise Shifting of Ailing Soren
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Biocon Shift Focus Innovation Accelerate Growth

(Date:12/17/2014)... (PRWEB) December 17, 2014 HeartMath® ... authorities on stress, heart rate variability (HRV), heart ... licensing its extensive HRV databases and algorithms to ... opportunities will enable HeartMath’s partners to offer its ... extensive research, as well as its normative HRV ...
(Date:12/17/2014)... In its comprehensive analysis of medical ... Claim Review division have recently identified out-of-network and medical ... savings are achieved on behalf of employer-clients. , ... in savings to Argus each year, with a total ... by Tom Doney, Cypress president and CEO, these in-depth ...
(Date:12/17/2014)... Hill, IL (PRWEB) December 17, 2014 ... 2015 Awards celebrate the best of the best in ... The award is only given to communities and agencies ... through the SeniorAdvisor.com site. Of the nearly 100,000 providers ... this award. Winners of the SeniorAdvisor.com Best of 2015 ...
(Date:12/17/2014)... Dec. 15, 2014 (HealthDay News) -- As gas prices ... deaths, a new study suggests. In times of ... of those riders are inexperienced, the researchers explained. ... California, which has the highest number of motorcycle registrations ... of motorcyclist deaths. The analysis revealed a strong ...
(Date:12/17/2014)... Dec. 16, 2014 (HealthDay News) -- Expectant parents should ... and Drug Administration recommends. Use of ultrasound imaging ... is not entirely risk-free, the agency warns. ... harm due to ultrasound imaging and heartbeat monitors, prudent ... is important," Shahram Vaezy, an FDA biomedical engineer, said ...
Breaking Medicine News(10 mins):Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2
... apologized profusely for trying to smuggle human growth hormones and ... with importing banned substances into Australia in February this year ... ,A Customs search of his luggage at the start ... of the banned human growth hormone product, Jintropin. ...
... Exposure to second hand smoke is harmful for underweight ... babies with a low birth weight (5.5 pounds) have ... as coughing, wheezing and pulmonary infections up to age ... if these children are exposed to second hand smoke, ...
... Huxley has said that, "Although there was support for a ... of heart disease , the relationship is not as strong ... may have on heart disease are dwarfed by other risk ... ,Coronary heart disease is the leading cause ...
... International marathon to mobilize public support for the fight against ... ,The proceeds from the marathon, hosted by the ... Embassy of the United Arab Emirates (UAE), will go to ... ,More than 9000 entrants from around the world, including ...
... undergo chemotherapy, they experience fatigue and disruptions in ... study from the University of Nebraska Medical ... say their findings suggest that health professionals should ... any further medical procedures begin. Between 70 to ...
... looking for ways and means of limiting or even stopping ... complicated . ,Offering a way out Wyeth, US ... and Drug Administration (FDA) is expected to announce its approval ... would be the fourth new oral contraceptive that doesn't follow ...
Cached Medicine News:Health News:Sylvester Stallone Regrets Smuggling Banned Substances to Australia 2Health News:Sylvester Stallone Regrets Smuggling Banned Substances to Australia 3Health News:Research Suggests Breast Cancer Fatigue Begins Before Chemo 2Health News:Research Suggests Breast Cancer Fatigue Begins Before Chemo 3Health News:New Pill to Suppress Menstrual Bleeding Indefinitely 2Health News:New Pill to Suppress Menstrual Bleeding Indefinitely 3
(Date:12/19/2014)... 18, 2014   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... results from its pivotal field study of AT-001 ... in dogs with osteoarthritis.  In the study, dogs ... that were statistically significant compared to placebo (p<0.05) ...
(Date:12/17/2014)... Revenue and earnings above the previous ... development In the past 2013/14 fiscal year (ended ... to EUR 4.287 billion (last year: EUR 4.190 billion) despite ... EUR 360 million. "Overall, 2013/14 was a successful fiscal year ... President and CEO of Carl Zeiss AG. "Thanks to our ...
(Date:12/17/2014)... , December 17, 2014 ... nothing less than a hub of information concerning the biopharmaceutical ... A further addition to the recently launched institutional ... and has now been enriched by a new chapter in ... A richly detailed and panoramic hub on the ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... 2011 Henry Schein, Inc. (NASDAQ: ... services to office-based practitioners, announced today that Ferdinand ... the CL King 9th Annual Best Ideas Conference 2011. The ... New York City. Henry Schein,s presentation is ...
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... for human disease, reported positive data from a recently ... dual inhibitor of the sodium glucose transporters 1 and ... effects on multiple parameters of glycemic control and cardiovascular ...
Cached Medicine Technology:Henry Schein to Present at the CL King 9th Annual Best Ideas Conference 2011 2LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects 2LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects 3LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects 4
...
... is designed for laboratories looking for time ... in system operation in terms of easy ... calibration and on-board stability., ,URISYS 2400 ... enhanced walk-away capability for medium to high ...
Indicated for procedures of the wrist, ankle, elbow, and other small joints, the,UltrAblator is effective for ablation of soft tissue and coagulation of bleeders,encountered during surgery....
... Limited Wrist Fusion Plate was ... and a straightforward technique. As ... corner and other limited wrist ... kind of innovations upon which ...
Medicine Products: